vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and NorthEast Community Bancorp, Inc. (NECB). Click either name above to swap in a different company.
NorthEast Community Bancorp, Inc. is the larger business by last-quarter revenue ($26.4M vs $16.1M, roughly 1.6× Journey Medical Corp). NorthEast Community Bancorp, Inc. runs the higher net margin — 40.9% vs -7.8%, a 48.6% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 3.9%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs 1.8%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
NorthEast Community Bancorp, Inc. (MD) is a U.S.-based bank holding company operating primarily in the Mid-Atlantic region. It provides a comprehensive suite of consumer and commercial banking services, including deposit products, mortgage loans, small business financing, and wealth management solutions to individual and local enterprise clients.
DERM vs NECB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $26.4M |
| Net Profit | $-1.2M | $10.8M |
| Gross Margin | — | — |
| Operating Margin | -2.8% | 59.0% |
| Net Margin | -7.8% | 40.9% |
| Revenue YoY | 27.3% | 3.9% |
| Net Profit YoY | -182.0% | 5.8% |
| EPS (diluted) | $-0.04 | $0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $26.4M | ||
| Q3 25 | $17.0M | $27.0M | ||
| Q2 25 | $15.0M | $25.9M | ||
| Q1 25 | $13.1M | $25.5M | ||
| Q4 24 | $12.6M | $25.4M | ||
| Q3 24 | $14.6M | $27.6M | ||
| Q2 24 | $14.9M | $27.0M | ||
| Q1 24 | $13.0M | $25.5M |
| Q4 25 | $-1.2M | $10.8M | ||
| Q3 25 | $-2.3M | $11.9M | ||
| Q2 25 | $-3.8M | $11.2M | ||
| Q1 25 | $-4.1M | $10.6M | ||
| Q4 24 | $1.5M | $10.2M | ||
| Q3 24 | $-2.4M | $12.7M | ||
| Q2 24 | $-3.4M | $12.8M | ||
| Q1 24 | $-10.4M | $11.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | 47.7% | — |
| Q4 25 | -2.8% | 59.0% | ||
| Q3 25 | -9.0% | 61.6% | ||
| Q2 25 | -19.2% | 59.5% | ||
| Q1 25 | -25.3% | 57.4% | ||
| Q4 24 | 17.7% | 57.0% | ||
| Q3 24 | -19.8% | 63.6% | ||
| Q2 24 | -19.7% | 65.6% | ||
| Q1 24 | -77.4% | 62.7% |
| Q4 25 | -7.8% | 40.9% | ||
| Q3 25 | -13.6% | 44.0% | ||
| Q2 25 | -25.3% | 43.1% | ||
| Q1 25 | -31.0% | 41.4% | ||
| Q4 24 | 12.1% | 40.1% | ||
| Q3 24 | -16.3% | 45.9% | ||
| Q2 24 | -22.6% | 47.5% | ||
| Q1 24 | -80.1% | 44.5% |
| Q4 25 | $-0.04 | $0.78 | ||
| Q3 25 | $-0.09 | $0.87 | ||
| Q2 25 | $-0.16 | $0.82 | ||
| Q1 25 | $-0.18 | $0.78 | ||
| Q4 24 | $0.10 | $0.74 | ||
| Q3 24 | $-0.12 | $0.95 | ||
| Q2 24 | $-0.17 | $0.97 | ||
| Q1 24 | $-0.53 | $0.86 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $81.2M |
| Total DebtLower is stronger | $25.3M | $70.0M |
| Stockholders' EquityBook value | $31.9M | $351.7M |
| Total Assets | $94.6M | $2.1B |
| Debt / EquityLower = less leverage | 0.79× | 0.20× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $81.2M | ||
| Q3 25 | $24.9M | $64.3M | ||
| Q2 25 | $20.3M | $59.4M | ||
| Q1 25 | $21.1M | $89.5M | ||
| Q4 24 | $20.3M | $78.3M | ||
| Q3 24 | $22.5M | $97.8M | ||
| Q2 24 | $23.9M | $113.9M | ||
| Q1 24 | $24.1M | $107.4M |
| Q4 25 | $25.3M | $70.0M | ||
| Q3 25 | $25.2M | $170.0M | ||
| Q2 25 | $25.1M | $135.0M | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | $7.0M | ||
| Q2 24 | $19.7M | $47.0M | ||
| Q1 24 | $14.7M | $47.0M |
| Q4 25 | $31.9M | $351.7M | ||
| Q3 25 | $25.9M | $344.0M | ||
| Q2 25 | $19.2M | $336.7M | ||
| Q1 25 | $21.5M | $327.2M | ||
| Q4 24 | $20.1M | $318.3M | ||
| Q3 24 | $10.9M | $309.6M | ||
| Q2 24 | $11.3M | $300.0M | ||
| Q1 24 | $13.0M | $288.9M |
| Q4 25 | $94.6M | $2.1B | ||
| Q3 25 | $85.2M | $2.1B | ||
| Q2 25 | $81.2M | $2.0B | ||
| Q1 25 | $85.0M | $1.9B | ||
| Q4 24 | $80.2M | $2.0B | ||
| Q3 24 | $64.0M | $2.0B | ||
| Q2 24 | $65.2M | $1.9B | ||
| Q1 24 | $66.6M | $1.9B |
| Q4 25 | 0.79× | 0.20× | ||
| Q3 25 | 0.97× | 0.49× | ||
| Q2 25 | 1.30× | 0.40× | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | 0.02× | ||
| Q2 24 | 1.75× | 0.16× | ||
| Q1 24 | 1.13× | 0.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $52.6M |
| Free Cash FlowOCF − Capex | — | $50.8M |
| FCF MarginFCF / Revenue | — | 192.3% |
| Capex IntensityCapex / Revenue | — | 6.6% |
| Cash ConversionOCF / Net Profit | — | 4.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | $89.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $52.6M | ||
| Q3 25 | $-2.4M | $14.1M | ||
| Q2 25 | $-942.0K | $15.6M | ||
| Q1 25 | $-2.8M | $10.9M | ||
| Q4 24 | $2.2M | $48.7M | ||
| Q3 24 | $-1.2M | $14.4M | ||
| Q2 24 | $-5.2M | $11.1M | ||
| Q1 24 | $-5.0M | $12.9M |
| Q4 25 | — | $50.8M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $14.9M | ||
| Q1 25 | — | $10.6M | ||
| Q4 24 | — | $48.2M | ||
| Q3 24 | — | $14.2M | ||
| Q2 24 | — | $11.0M | ||
| Q1 24 | — | $12.8M |
| Q4 25 | — | 192.3% | ||
| Q3 25 | — | 50.5% | ||
| Q2 25 | — | 57.3% | ||
| Q1 25 | — | 41.4% | ||
| Q4 24 | — | 189.3% | ||
| Q3 24 | — | 51.5% | ||
| Q2 24 | — | 40.8% | ||
| Q1 24 | — | 50.3% |
| Q4 25 | — | 6.6% | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | — | 2.9% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.0% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | — | 4.86× | ||
| Q3 25 | — | 1.18× | ||
| Q2 25 | — | 1.40× | ||
| Q1 25 | — | 1.04× | ||
| Q4 24 | 1.46× | 4.77× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 0.87× | ||
| Q1 24 | — | 1.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
NECB
Segment breakdown not available.
